Cadrenal Therapeutics(US:CVKD)2024-11-07 14:10Financial Results - Cadrenal Therapeutics, Inc. reported financial results for the fiscal quarter ended September 30, 2024[4]. - The company issued a press release on November 7, 2024, detailing its financial performance[4]. Regulatory Information - The report is not deemed "filed" under the Securities Exchange Act of 1934, ensuring it is not subject to certain liabilities[5]. - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The press release is attached as Exhibit 99.1 to the Current Report on Form 8-K[6]. - The financial statements and exhibits are furnished with the Current Report on Form 8-K[6]. - The report was signed by Quang Pham, Chairman and CEO of Cadrenal Therapeutics, Inc.[7]. Company Information - The company is headquartered in Ponte Vedra, Florida[2]. - The trading symbol for the company's common stock is CVKD on the Nasdaq Capital Market[3]. - The company has not elected to use the extended transition period for new financial accounting standards[4].